Long-term efficacy and safety of ublituximab in the treatment of multiple sclerosis: A critical review of medical literature.

Authors

Ali Ariyaei Motahar, Mohammad Ali Sahraian, Alireza Minagar

Published in

Multiple sclerosis and related disorders. Volume 115. Pages 107881. Aug 26, 2026. Epub Aug 26, 2026.

Abstract

Ublituximab(UTX) is a novel, glycoengineered anti-CD20 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) that enables efficient B-cell depletion at lower doses and shorter infusion times compared to other anti-CD20 therapies. This critical review synthesizes evidence on the long-term efficacy and safety of UTX in relapsing forms of multiple sclerosis (MS).
To critically evaluate ublituximab's long-term efficacy and safety in relapsing MS via clinical evidence synthesis.
We reviewed peer-reviewed literature, clinical trials, extension studies, observational reports, and recent conference posters/abstracts, providing a qualitative overview.
UTX shows sustained disease control, including reduced relapses and MRI activity, over extended periods in relapsing MS patients. B-cell depletion remains effective long-term, with a safety profile typical of anti-CD20 therapies, including manageable infusion reactions and stable monitoring for infections and immunoglobulins.
UTX represents a potent, efficient disease-modifying therapy for relapsing MS with robust, durable efficacy comparable to other anti-CD20 agents. Its primary clinical advantage is the streamlined one-hour maintenance infusion every 24 weeks. While the absence of head-to-head trials against other high-efficacy agents and knowledge gaps regarding long-term safety in diverse populations remain limitations, current evidence supports ublituximab's position in aggressive early-treatment strategies, provided that clinical vigilance for cumulative risks such as hypogammaglobulinemia is maintained. Future research should prioritize comparative trials, investigation in progressive MS phenotypes, and validation of optimized dosing strategies.

PMID:
42691808
Bibliographic data and abstract were imported from PubMed on 04 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.